Viral and bacterial aetiologies of epithelial ovarian cancer
- 641 Downloads
We sought to analyse the presence of human papillomavirus (HPV), Chlamydia trachomatis and cytomegalovirus (CMV) infection in women with epithelial ovarian carcinomas. Polymerase chain reaction (PCR)-based detection of microbial infections was carried out. A total of 39 tissue samples were analysed with consensus and type-specific primers for HPV, primers specific for the cryptic plasmid of Chlamydia and primers for glycoprotein B of CMV. The samples analysed showed 40%, 80% and 50% positivity for HPV, Chlamydia and CMV infection, respectively, in cancerous ovarian tissues. The HPV type detected was HPV 6, with its genome integrated to the host genome in case of both invasive and borderline tumours and existed episomally in healthy controls. The patients with Chlamydia (odds ratio [OR] 32; 95% confidence interval [CI] 3.33, 307.65) and CMV infection (OR 8; 95% CI 0.888, 72.10) are at significantly higher risk of development of ovarian tumours. The present study validates the theory of chronic infections and inflammation in the pathogenesis of epithelial ovarian cancer. Further seroepidemiological studies and large fresh tissue sampling may represent the real prevalence of infections among ovarian carcinoma patients. This study is the first of its kind in detecting the bacterial and viral aetiologies in the development of ovarian carcinoma among Indian women.
KeywordsOvarian Carcinoma Epithelial Ovarian Cancer Ovarian Tissue Chlamydia Trachomatis Borderline Tumour
K.N. is thankful to the Indian Council of Medical Research (ICMR; 5/13/88/06/NCD-III) for providing financial support to carry out the research work. S.S. is thankful to the ICMR for providing the Senior Research Fellowship (3/2/2/63/2011/NCD-III). The authors greatly acknowledge the Vice-Chancellor of Bharathidasan University and Dr. V.J. Senthil, the Director of GVN Hospital, Tiruchirappalli, Tamilnadu, India.
Conflict of interest
The authors declare no conflict of interest.
- 3.Idahl A, Lundin E, Jurstrand M, Kumlin U, Elgh F, Ohlson N, Ottander U (2011) Chlamydia trachomatis and Mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors. Infect Dis Obstet Gynecol 2011:824627. doi: 10.1155/2011/824627
- 5.Koskela P, Anttila T, Bjørge T, Brunsvig A, Dillner J, Hakama M, Hakulinen T, Jellum E, Lehtinen M, Lenner P, Luostarinen T, Pukkala E, Saikku P, Thoresen S, Youngman L, Paavonen J (2000) Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 85:35–39PubMedCrossRefGoogle Scholar
- 10.Bauer HM, Greer CE, Manos MM (1992) Determination of genital HPV infection using consensus PCR. In: Herrington CS, McGee JOD (eds) Diagnostic molecular pathology: a practical approach. Oxford University Press, Oxford, pp 131–152Google Scholar
- 16.Shah KV, Howley PM (1996) Papillomaviruses. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, vol 2. Lippincott-Raven, Philadelphia, pp 2077–2109Google Scholar
- 17.Dillner J, Lehtinen M, Björge T, Luostarinen T, Youngman L, Jellum E, Koskela P, Gislefoss RE, Hallmans G, Paavonen J, Sapp M, Schiller JT, Hakulinen T, Thoresen S, Hakama M (1997) Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 89:1293–1299PubMedCrossRefGoogle Scholar
- 21.Idahl A, Lundin E, Elgh F, Jurstrand M, Møller JK, Marklund I, Lindgren P, Ottander U (2010) Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus, and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline tumor, or benign conditions. Am J Obstet Gynecol 202:71.e1–71.e6CrossRefGoogle Scholar
- 35.Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Burk RD, Rodriguez AC, Alfaro M, Hutchinson ML, Morales J, Schiffman M (2001) An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 10:1021–1027PubMedGoogle Scholar